Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and CC-99282 in Previously Untreated High Tumor Burden Follicular Lymphoma
NCT06108232Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golcadomide in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 1 year and Complete Response Rate. Started Mar 2024; status: recruiting.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06108232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108232.